About Us

What we do

Pharmity is an independent partner providing quality management consulting services. These include expert Good Clinical Practice (GCP) advice, quality assurance, quality management, audit and training.

Our service offerings reflect the expertise within Pharmity.

Our main experience is in GCP. We offer in-depth Clinical Quality Assurance (CQA) knowledge gained during multiple years working in the pharmaceutical, biotech and CRO industries.

Contact us

At Pharmity, consulting is more than giving advice.

Our Leadership

Dr Leire Zúñiga

Founder & Director

Dr Leire Zúñiga is the founder, Director and Principal Consultant of Pharmity. She has worked in the Pharmaceutical, Biotech and CRO industries since 2003 within Quality Assurance.

Leire received her Ph.D. in Pharmacy from the Faculty of Pharmacy - University of the Basque Country (Spain) in 2009 (Cum Laude; Extraordinary Doctorate Award). Her thesis focused on biosimilars.

Just before setting up Pharmity, Leire worked as Senior Quality Assurance Manager in one of the top ten CROs working as part of a global compliance team for internal and external clients worldwide.

Leire has developed an in depth knowledge in Quality Assurance. She has contributed to the development and maintenance of Good Practice (GxP) quality systems and audit programs for more than 15 years.

During this time Leire has conducted numerous international audits. She has also hosted GCP regulatory inspections from the EMA, MHRA, other EU Regulatory Inspectorates during her career.

Leire is recognized for her strong auditing and analytical skills. She shares a passion for compliance, process improvement and staff training/development. She has contributed to build high-performing teams during her career.

Leire is an active member in the GxP Working Groups of AEFI since more than 15 years. In addition, she is also member of ISPE and RQA.

Leire is a regular speaker at national conferences covering mainly GCP Compliance and Quality Assurance, Auditing, eSystems validation (SDLC approach), Biosimilars.

Read our latest publications

Go to our Blog